Methylation Analysis for Non-Surgical Therapy Study of HER2+ ER- Breast Cancer
Open tenderJapanese title: 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評価する前向き研究に係るメチル化解析 一式
Overview
This procurement is for methylation analysis related to a prospective study evaluating the usefulness of non-surgical therapy in HER2 positive ER negative breast cancer with high methylation of the gene HSD17B4. The contract includes all related costs and will be performed at the National Cancer Center East Hospital. The deadline for bid submission is October 6, 2026.
Key Details
- Source: KKJ
- Notice type: Open tender
- Publication date: September 10, 2026
- Procuring entity: Manno Hiroyuki, Director of the National Cancer Center
- Submission deadline: October 6, 2026, 17:00 JST
- Bid opening: October 7, 2026, 11:00 JST
- Award method: Lowest-price award
- Eligibility (from notice): All-ministry unified qualification, 'services', grade A–D, Kanto-Koshinetsu region – verify in the tender documents
- Status: Active
- Technology relevance: Possible
- Business-action likelihood: Medium – The procurement requires specialized biomedical analysis and is open competitive bidding, but local participation qualifications and detailed specifications may require partnerships or adaptation.
Official Notice
Official Source
KKJ, Japan's Government Procurement Information Website, which aggregates procurement notices from national and local public-sector organizations.
- Source: KKJ (Government Procurement Information Website)
- Official category: 一般競争入札
- Publication date: September 10, 2026
- Publication: Official notice document (PDF)
Full English Translation
The following English translation was prepared from the original Japanese notice published by the procuring entity and listed on KKJ, Japan's Government Procurement Information Website. The translation below is based on the Japanese source text.
The following is subject to open competitive bidding.
September 10, 2026
National Research and Development Agency
National Cancer Center Director Manno Hiroyuki
◎ Procurement Agency Number 819 ◎ Location Number 12
1 Procurement Details
(1) Procurement Subject and Quantity
Methylation analysis related to the 'Prospective study evaluating the usefulness of non-surgical therapy in HER2 positive ER negative breast cancer with high methylation of gene HSD17B4' - one set
(2) Characteristics of the Procurement Subject
According to the bidding documents and specifications.
(3) Performance Deadline
According to the bidding documents and specifications.
(4) Performance Location
National Research and Development Agency National Cancer Center East Hospital
(5) Bidding Method
The decision of the negotiation rights holder will be made by the lowest price method,
① Bidders must estimate the contract amount including direct expenses related to the procurement subject, equipment, materials, machinery, transportation costs, outsourcing fees, and all other expenses.
② When deciding the negotiation rights holder, the amount obtained by adding 10% of the amount stated in the bid document (fractions less than 1 yen are rounded down) will be the application amount. Bidders must submit a bid stating the amount equivalent to 100/110 of the estimated contract amount regardless of whether they are taxable or tax-exempt businesses for consumption tax and local consumption tax.
2 Eligibility for Competition Participation
(1) Must not fall under the provisions of Article 6 of the National Cancer Center Contract Handling Rules. Minors, persons under guardianship or assistance who have obtained necessary consent for contract conclusion may be exceptions.
(2) Must not fall under the provisions of Article 7 of the National Cancer Center Contract Handling Rules.
(3) Must be rated A, B, C, or D in the qualification examination result notification (unified qualification for all ministries) for 'Provision of services, etc.' and have competition participation qualification in the Kanto-Koshinetsu region.
(4) Must be enrolled in social insurance and have no arrears in insurance premiums for the past two years.
3 Submission Location of Bid Documents, etc.
(1) Submission and inquiry location
National Research and Development Agency National Cancer Center East Hospital
Kashiwa C Finance and Accounting Section Research Affairs
6-5-1 Kashiwanoha, Kashiwa City, Chiba Prefecture 277-8577
Phone 04-7130-0222 ext. 2375
(2) Method of distribution of bidding documents
Distributed at the location in (1).
(3) Deadline for receipt of bids
October 6, 2026, 17:00
(4) Opening date and location
October 7, 2026, from 11:00
National Cancer Center East Hospital, 3rd floor, 2nd Conference Room
4 Others
(1) Language and currency used in contract procedures
Japanese and Japanese currency
(2) Bid and contract guarantees
Exempted
(3) Requirements for bidders
Bidders wishing to participate must submit sealed bids with documents proving capability to perform the work by the bid receipt deadline. Bidders must respond to explanations requested by contract officers before the bid opening day.
(4) Invalid bids
Bids submitted by ineligible bidders or those who fail to fulfill obligations will be invalid.
(5) Necessity of contract document
Required
(6) Method of contractor decision
The contractor will be the bidder who submits a bid with attached documents meeting all qualifications and specifications, whose bid is within the estimated price limits, and who offers the lowest price.
(7) Details are according to the bidding documents.
Show original Japanese notice
入札公告
次のとおり一般競争入札に付します。令和8年9月10日国立研究開発法人国立がん研究センター理事長間野博行◎調達機関番号819 ◎所在地番号12１ 調達内容(1)調達件名及び数量『遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評価する前向き研究』に係るメチル化解析一式(2)調達件名の特質等入札説明書及び仕様書による。 (3) 履行期限入札説明書及び仕様書による。 (4) 履行場所 国立研究開発法人国立がん研究センター東病院(5)入札方法交渉権者の決定は、最低価格方式をもって行うので、① 入札者が提出する入札書は、調達件名にかかる直接経費の他、機材、資材、機械器具、運搬費、業務委託に要する費用等、一切の諸経費を含め、契約金額を見積もるものとする。② 交渉権者決定にあたっては、入札書に記載された金額に当該金額の１０％に相当する額を加算した金額（当該金額に１円未満の端数がある場合は、その端数金額を切り捨てた金額とする。）をもって申込金額とするので、入札者は、消費税及び地方消費税に係る課税事業者であるか免税事業者であるかを問わず、見積もった契約金額の１１０分の１００に相当する金額を記載した入札書を提出しなければならない。２ 競争参加資格(1)国立研究開発法人国立がん研究センター契約事務取扱細則第６条の規定に該当しない者であること。なお、未成年者、被保佐人又は被補助人であっても、契約締結のために必要な同意を得ている者は、同条中、特別の理由がある場合に該当する。(2)国立研究開発法人国立がん研究センター契約事務取扱細則第７条の規定に該当しない者であること。(3)資格審査結果通知書（全省庁統一参加資格）「役務の提供等」で「Ａ」、「Ｂ」、「Ｃ」又は「Ｄ」等級に格付けされ、関東・甲信越地域の競争参加資格 を有する者であること。(4)社会保険等（厚生年金保険、健康保険（全国健康保険協会が管掌するもの）、船員保険、国民年金、労働者災害補償保険及び雇用保険をいう。）に加入し、該当する制度の保険料の滞納がないこと。（直近２年間の社会保険料及び労働保険料の未納がないこと。）３ 入札書の提出場所等(1)入札書の提出場所、契約条項を示す場所入札説明書の交付場所 及び問い合わせ先〒２７７－８５７７千葉県柏市柏の葉６－５－１国立研究開発法人国立がん研究センター東病院柏Ｃ財務経理課研究業務係電話０４－７１３０－０２２２内線２３７５(2)入札説明書の交付方法 (1)の交付場所にて交付する。(3)入札書の受領期限令和8年10月6日17時00分 (4) 開札の日時及び場所令和8年10月7日11時00分～国立研究開発法人国立がん研究センター東病院病院棟3階第二会議室４ その他(1)契約手続において使用する言語及び通貨日本語及び日本国通貨(2)入札保証金 及び契約保証金 免除(3)入札者に要求される事項この一般競争に参加を希望する者は、封印した入札書に本公告に示した業務が履行できることを証明する書類を添付して入札書の受領期限 までに提出しなければならない。入札者は、開札日の前日までの間において、契約担当者等から当該書類に関し説明を求められた場合には、これに応じなければならない。(4)入札の無効本公告に示した競争参加資格 のない者の提出した入札書、入札者に求められる義務を履行しなかった者の提出した入札書は無効とする。(5)契約書作成の要否 要(6)契約者の決定方法本公告及び入札説明書に従い、書類・資料を添付した入札書を提出した入札者であって、本入札公告及び入札説明書の競争参加資格 及び仕様書の要求、要件を全て満たし、当該入札者の入札書が国立研究開発法人国立がん研究センター契約事務取扱細則第３７条及び３８条の規定に基づいて作成された予定価格の制限の範囲内であり、かつ、最低の価格をもって入札を行った者を交渉権者とし、契約交渉の相手方とする。(7)詳細は入札説明書による。
Business Signal
Business Relevance
May interest companies providing specialized genetic methylation analysis services or advanced biomedical research support related to cancer therapy studies.
Participation fit
Participation is expected to require appropriate Japanese government procurement eligibility, or cooperation with a suitable Japanese partner holding the required qualification. The eligibility requirements have not been fully reviewed and should be verified against the official tender documents.
This page is based on the official procurement notice published by the procuring entity and listed on KKJ, Japan's Government Procurement Information Website, with translation and a preliminary business assessment by I.J. Do. The official Japanese notice and tender documents are binding.
JBid is a beta technology-procurement intelligence service by I.J. Do.